Recce Pharma

47 articles with Recce Pharma

• Recce Pharmaceuticals Announces Anti-Viral Patent Granted in China for RECCE® Anti-Infectives

  7/21/2021

  Recce Pharmaceuticals Ltd is pleased to announce the Chinese Patent Office has granted Patent Family 3 “ Anti-Virus Agent and Method for Treatment Of Viral Infections ”

• Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates Outstanding Efficacy Against Necrotizing Fasciitis ‘Flesh-Eating’ Bacteria

  7/20/2021

  RECCE is pleased to announce positive efficacy of RECCE® 327 (R327) against Clostridium perfringens (C. perfringens) and Streptococcus pyogenes (S. pyogenes), two main strains of bacteria associated with necrotizing fasciitis, also known as ‘flesh-eating’ disease – a life-threatening bacterial infection with a mortality rate of up to 80%.

• Recce Pharmaceuticals to Present at World Microbe Forum

  6/21/2021

  Recce Pharmaceuticals Ltd has accepted an invitation to present at the World Microbe Forum following confirmation to publish a recent abstract in the 2021 program.

• Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Progresses to Stage 2 of SARS-CoV-2 Antiviral Screening Program at CSIRO

  5/20/2021

  Further study completed at the Doherty Institute as part of SARS-CoV-2 Antiviral Screening Program calculates IC50 of RECCE® 327 (R327) to be 2,046 PPM and the CC50 for R327 to be 5108 PPM

• Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE® 327 Against All Six ESKAPE Pathogens

  5/4/2021

  More than 99.9% effective against full suite of ESKAPE pathogens, within hours of exposure to RECCE® 327 (R327) in independent bacterial efficacy studies

• Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange - Mar 09, 2021

  3/9/2021

  Recce Pharmaceuticals Ltd, the Company developing new classes of synthetic anti-infectives is pleased to announce the Company’s shares are now Dual Listed on the Frankfurt Stock Exchange

• Recce Pharmaceuticals Applies for Dual Listing on FSE (Frankfurt Stock Exchange)

  2/24/2021

  Recce Pharmaceuticals Ltd, the Company developing new classes of synthetic anti-infectives is pleased to announce it has commenced the application process to dual list its stock on the Frankfurt Stock Exhange.

• Recce Pharmaceuticals Announces Agreement with Fiona Stanley Hospital for a Phase 1/2 Clinical Trial Evaluating Topical Spray-On Antibiotic RECCE® 327 on Chronic Burn Wounds

  2/16/2021

  Highlights: Phase I/II trial agreement with Fiona Stanley Hospital (Burns Unit) in Perth Western Australia Study led by world leading burn treatment specialists Study will assess safety and efficacy of RECCE ® 327 against a broad range of infectious disease on chronic burn wounds in up to 30 patients   

• 

  New and Emerging Drug Classes That Will Outlast the Pandemic

  1/5/2021

  From synthetic polymer-based anti-infectives to antiviral conjugates and DNA vaccines, the past year has given new and emerging drug classes an opportunity to shine.

• Recce Announces Positive Intranasal Animal Data against SARS-CoV-2 in International Study

  12/23/2020

  Highlights: RECCE ® 327 and RECCE ® 529 demonstrated dose-dependent activity in-vivo against SARS-CoV-2 virus in Syrian golden hamsters, a well-accepted model of infection Intranasal administration of both compounds supports multiple potential modes of administration against SARS-CoV-2 Company committed to its COVID-19 activities as part of its infectious disease portfolio

• Recce Pharmaceuticals Provides Business Update

  12/21/2020

  Recce Pharmaceuticals Ltd ( ASX: RCE ), the Company developing new classes of synthetic anti-infectives, is pleased to provide an update on its clinical programs. Topical Phase I/II Human Clinical Trial Submission Topical Phase I/II human clinical study is on track and progressing well. The Company recently announced it has received Human Research Ethics Approval for its Phase I/II human topical clinical trial in infected burn wounds an

• Recce Pharmaceuticals Announces Anti-viral Patent Granted in Japan for RECCE® Anti-Infectives

  11/23/2020

  Recce Pharmaceuticals Ltd ( ASX: RCE ), the Company developing new classes of synthetic anti-infectives, is pleased to announce the Japan Patent Office (JPO) has granted Patent Family 3 titled “Anti-virus Agent and Method for Treatment of Viral Infection” , furthering marketing and manufacturing monopolies to February 2037. “Recce’s intellectual property portfolio continues to grow in-line with our business strategy and the unprecedented

• Recce Pharmaceuticals Receives Ethics Approval to Start Phase I/II Study Evaluating Topical Spray-On Synthetic Antibiotic RECCE® 327 on Chronic Burn Wounds

  10/19/2020

  Highlights : Study will assess safety and efficacy of RECCE ® 327 against a broad range of infectious bacteria on chronic burn wounds in up to 30 patients over two week period Study anticipated to be sponsored by South Metropolitan Health Service , Department of Health, Government of Western Australia (WA) Fiona Stanley Hospital ( B urns U nit) in Perth Western Australia identified as study site SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE)

• Recce Pharmaceuticals and Murdoch Children’s Research Institute to Evaluate RECCE® 435 Against Helicobacter pylori Stomach Bacteria

  9/30/2020

  Highlights : Murdoch Children’s Research Institute to evaluate the in-vivo antimicrobial activity of RECCE ® 435 oral formulation against Helicobacter pylori (H. pylori) in preclinical studies program Studies led by H. pylori infectious disease expert Professor Philip Sutton Multiple world-first data opportunities over 12 months study program – anticipated human clinical trial beyond  SYDNEY, Australia, Sept. 30, 2020 (GLOBE NEWSWIRE) -- Recce Pharma

• 

  BioSpace Movers & Shakers, Sept. 4

  9/4/2020

  Biopharma and life science companies from across the globe strengthen their leadership teams and boards with these Movers & Shakers.
• 

  BioSpace Global Roundup, Sept. 3

  9/3/2020

  Biopharma and life science companies from across the globe provide updates on their pipelines and businesses.

• Recce Pharmaceuticals Announces Positive Oral Data on New RECCE® 435 Against Helicobacter Pylori in Animal Model

  8/5/2020

  Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, announced positive efficacy activity against Helicobacter pylori bacteria in rats treated with new antibiotic RECCE® 435, including a favorable toxicity profile in a related study.

• Recce Pharmaceuticals to Give Opening R&D Address at 2020 Virtual World Antibiotic Resistance Congress

  7/27/2020

  Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Company ), the Company developing New Classes of Synthetic Anti-infectives, today announced that it will be delivering the Opening R&D Address at the World Anti-Microbial Resistance (AMR) Congress from the 8th – 9th October 2020. Due to the global pandemic, the conference will be held entirely virtually.  The two-day World AMR Congress is the largest commercially focused conference with AMR at i

• 

  Biopharma Update on the Novel Coronavirus: July 17

  7/17/2020

  Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 17, 2020.

• Recce Pharmaceuticals Enters Agreement with Path BioAnalytics to Test RECCE® Compounds in Expanded SARS-CoV-2 Program

  7/16/2020

  Highlights: International study will be conducted in a laboratory at a leading academic institution in the U.S. to evaluate anti-viral activity of RECCE ® 327 and new antiviral formulation RECCE ® 529 Expanded program utilizing Centers for Disease Control (CDC) SARS-CoV-2 clinical isolate SARS-Related Coronavirus 2, Isolate USA-WA1/2020 Preliminary data anticipated September 2020 SYDNEY, Australia, July 16, 2020 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd ( ASX: RCE ) ( Compa